Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 98319-26-7 | Product Number: F0675
Finasteride
×
![]()
×
Purity: >98.0%(GC)
Synonyms:
- N-tert-Butyl-3-oxo-4-aza-5α-androst-1-en-17β-carboxamide
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 200MG |
$59.00
|
2 | 1 | 1 |
|
| 1G |
$173.00
|
3 | 2 | 33 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | F0675 |
| Purity / Analysis Method | >98.0%(GC) |
| Molecular Formula / Molecular Weight | C__2__3H__3__6N__2O__2 = 372.55 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image), 200MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 98319-26-7 |
| Reaxys Registry Number | 4269024 |
| PubChem Substance ID | 87560747 |
| Merck Index (14) | 4082 |
| MDL Number | MFCD00869737 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(GC) | min. 98.0 % |
Properties (reference)
| Melting Point | 253 °C |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
Related Laws:
| RTECS# | CL5245000 |
Transport Information:
| HS Number | 2937.29.9050 |
Application
Biofilm research
Reference
- In Vitro Analysis of Finasteride Activity against Candida albicans Urinary Biofilm Formation and Filamentation
Application
Finasteride: The First Type2 5α-Reductase Inhibitor
Finasteride, the first type2 5α-reductase inhibitor, blocks the conversion of testosterone [T0027] to 5α-dihydrotestosterone (DHT) [A0462] in target organs such as the prostate and scalp hair. Finasteride also has been studied for its ability to reduce the incidence of prostate cancer. (The product is for research purpose only.)
References
- Finasteride: An update of its use in the management of symptomatic benign prostatic hyperplasia (a review)
- Finasteride: a review of its use in male pattern hair loss
- A new look at the 5α-reductase inhibitor finasteride (a review)
- The rationale for inhibiting 5α-reductase isoenzymes in the prevention and treatment of prostate cancer (a review)
- Type 1 and type 2 5α-reductase expression in the development and progression of prostate cancer (a review)
- An overview on 5α-reductase inhibitors
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.